Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
NUVB vs RCUS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
NUVB Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–3 Matrix Metrics)
NUVB Overall Winner
6-Pillar Tally: NUVB 4 – 1 RCUS (1 Tie)
Matrix Metrics: NUVB 5 – 3 RCUS
As of Nov 20, 2026, Nuvation Bio Inc. (NUVB) is the stronger overall head-to-head candidate over Arcus Biosciences, Inc. (RCUS) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NUVB carries a Unified Composite Score of 61.0/100 (BUY) at $3.80 (N/M Forward P/E, -61.2% operating margin), whereas RCUS carries 48.9/100 (HOLD) at $15.62 (N/M Forward P/E, -475.0% operating margin).
- Technical & Structure Timing Caution: NUVB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3); meanwhile RCUS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About NUVB vs RCUS
NUVB
Head-to-Head Winner
Nuvation Bio Inc.
$3.80
-0.26% 1D
Market Cap
$1.3B
TTM Revenue
$202M
Forward P/E
N/M
Beta / 30D Vol
1.52β · 55% Vol
Unified Composite Score
61.0
BUY
Tech 53.0
Fund 61.0
Flow 67.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
RCUS
Arcus Biosciences, Inc.
$15.62
-1.01% 1D
Market Cap
$2.3B
TTM Revenue
$100M
Forward P/E
N/M
Beta / 30D Vol
1.39β · 54% Vol
Unified Composite Score
48.9
HOLD
Tech 44.0
Fund 56.0
Flow 70.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (NUVB 4 – 1 RCUS)
1. Valuation Multiples
NUVB
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
7.4x
22.4x
2. Growth & Scale
NUVB
Revenue Growth (YoY)
+242.6%
-65.4%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$202M
$100M
Market Cap
$1.3B
$2.3B
3. Profitability & Quality
NUVB
Gross Margin
85.8%
N/A
Operating Margin
-61.2%
-475.0%
Net Profit Margin
-67.4%
0.0%
Return on Equity (ROE)
-49.1%
-114.1%
4. Balance Sheet & Cash Flow
NUVB
Cash Generation (TTM)
-$108M
-$466M
Cash Flow Margin
-53.6%
N/A
Net Cash / Leverage
$146M Net Debt (1.32x D/E)
$35M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
RCUS
Options Structure Phase
BREAKDOWN
BREAKDOWN
Current IV / %ile
65.2% (26th %ile)
98.2% (11th %ile)
Put/Call OI Skew
0.24x (Call-Skewed)
0.01x (Call-Skewed)
OBV Trend / Tech Phase
DISTRIBUTION · Markdown
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: NUVB (5) vs RCUS (3)| Institutional Metric | NUVB | RCUS | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $1.3B | $2.3B | RCUS | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +242.6% | -65.4% | NUVB | |
| Operating Margin (TTM) | -61.2% | -475.0% | NUVB | |
| Net Profit Margin | -67.4% | 0.0% | RCUS | |
| Return on Equity (ROE) | -49.1% | -114.1% | NUVB | |
| 52-Week Range Position | 2% ($4–$10) | 0% ($16–$32) | NUVB | |
| Beta / 30D Volatility | 1.52β · 55% Vol | 1.39β · 54% Vol | RCUS | |
| Unified Institutional Score | 61.0 / 100 (BUY) | 48.9 / 100 (HOLD) | NUVB | |
| Trailing 12M Revenue (USD) | $202M | $100M | Scale | |
| Gross Profit Margin (TTM) | 85.8% | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 7.4x EV/Rev | N/M PEG · 22.4x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$108M ($146M Net Debt (1.32x D/E)) | -$466M ($35M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
NUVB +0.17 pp
3M Horizon
NUVB +4.35 pp
6M Horizon
NUVB +13.84 pp
1Y Horizon
RCUS +24.1 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | NUVB Revenue | RCUS Revenue | NUVB Op. Margin | RCUS Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | N/A | $10M | N/A | -656.8% | RCUS |
| FY2019 | N/A | $10M | N/A | -591.4% | RCUS |
| FY2020 | N/A | $80M | N/A | -159.0% | RCUS |
| FY2021 | N/A | $380M | N/A | 14.1% | RCUS |
| FY2022 | N/A | $40M | N/A | -736.8% | RCUS |
| FY2023 | N/A | $40M | N/A | -918.9% | RCUS |
| FY2024 | $10M | $50M | -7527.3% | -647.1% | RCUS |
| FY2025 | $60M | $30M | -338.7% | -1169.7% | NUVB |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
NUVB
BREAKDOWN
Current IV
65.2%
IV Percentile
26th %ile
Put/Call OI Skew
0.24x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact NUVB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
RCUS
BREAKDOWN
Current IV
98.2%
IV Percentile
11th %ile
Put/Call OI Skew
0.01x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
DISTRIBUTION
Exact RCUS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
NUVB Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
RCUS Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ NUVB vs RCUS Key Questions & Quantitative Answers
As of Nov 20, 2026, Nuvation Bio Inc. (NUVB) is the stronger overall head-to-head candidate over Arcus Biosciences, Inc. (RCUS) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NUVB carries a Unified Composite Score of 61.0/100 (BUY) at $3.80 (N/M Forward P/E, -61.2% operating margin), whereas RCUS carries 48.9/100 (HOLD) at $15.62 (N/M Forward P/E, -475.0% operating margin). Technical & Structure Timing Caution: NUVB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3); meanwhile RCUS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
NUVB leads the Growth & Scale pillar: NUVB posts +242.6% YoY revenue growth and +0.0% YoY earnings growth on $202M TTM revenue (85.8% gross margin, -61.2% operating margin), compared with RCUS at -65.4% YoY revenue growth and +0.0% YoY earnings growth on $100M TTM revenue (N/A gross margin, -475.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), NUVB cumulative revenue shifted +500.0% while RCUS shifted +200.0%. In operating R&D and SG&A reinvestment, NUVB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RCUS.
NUVB screens cheaper on headline valuation multiples. NUVB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.4x EV/Revenue (-53.6% FCF margin), whereas RCUS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 22.4x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NUVB (-49.1% ROE) versus RCUS (-114.1% ROE) capital efficiency.
In options market volatility and institutional positioning, NUVB carries 65.2% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.24x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.52β · 55% Vol realized risk). By comparison, RCUS carries 98.2% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.39β · 54% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
RCUS vs NUVB · Reverse Pair
NUVB vs LYEL
· Sector Peer
NUVB vs TSHA
· Sector Peer
NUVB vs STOK
· Sector Peer
RCUS vs SNDX
· Sector Peer
RCUS vs ARVN
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem